For instance, IMO-8400, a TLR7, 8, and 9 antagonists, exhibited clinical efficacy in a phase 2a randomized, placebo-controlled trial involving patients with moderate-to-severe plaque psoriasis.589 Preclinical assessments of MHV370, a selective oral inhibitor of TLR7/8, have been promising. The gene discussed is TLR7; the disease is psoriasis vulgaris.